Recursion Pharma Appoints Najat Khan As CEO
(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Wednesday announced that its Board of Directors has unanimously approved that Chief R&D and Commercial Officer Najat Khan will take over from Chris Gibson as Chief Executive Officer and President effective January 1, 2026.
Najat will also continue serving on the Board of Directors.
Gibson will transition to Chairman of the Board and interim Executive Advisor, while current Chairman Rob Hershberg will assume the role of Vice-Chairman and Lead Independent Director.
In the pre-market trading, Recursion Pharma is 1.2000% lesser at $4.9400 on the Nasdaq.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.